Driving long-term health by discovering, developing and delivering
We refuse to accept the status quo for people living with serious chronic diseases. For more than century, we have translated unmet medical needs into innovative medicines and delivery systems, like our insulin pens, and today we continue to reimagine what’s possible through bold science.
From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to people living with diabetes, obesity, and rare blood and endocrine diseases around the world.
Once a breakthrough treatment is created in our labs, we want it to reach as many people as possible. To keep up with demand, we scale fast. We build big. We optimise at every opportunity. By building capacity to a level previously unheard of in our industry, we can make a difference in more lives than ever before.
We focus on serious chronic diseases that affect hundreds of millions of people and are among the most urgent global health challenges. Drawing on insights from patients and partners, we transform unordinary ideas into life-saving and preventive medicines.
We make long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to continually advance the development of medical devices and digital health solutions.
Conquering serious chronic diseases requires a collective effort. We actively seek collaborations with individuals and organisations dedicated to improving patients' lives through research and prevention initiatives.
Throughout our work, we join forces with leading scientists, academic institutions, technology startups, biotech innovators, and pharmaceutical companies. This collaboration allows us to transform innovative ideas into effective solutions that reach patients worldwide.
Together, anything is possible.
Defeating diabetes and other serious chronic diseases is not something we can do alone.
In our research, development, production and commercial operations, we work with partners who complement our own expertise.
We are always on the lookout for new opportunities with people and organisations who are interested in collaborating to change patients’ lives, together.
Sometimes the best path to discovery is through open collaboration. We strongly believe in this.
From our open innovation challenges to the sharing of our molecular compounds for preclinical research, we aim to create new innovation ecosystems that accelerate new medicine discovery and better digital health solutions.
